Investor Presentaiton

Investor presentation ADA 2019 Slide 29 Novo Nordisk continues to invest in post-approval trials across the portfolio to support clinical findings in real-world settings OZEMPİC semaglutide injection Xultophy insulin degludec/liraglutide [rDNA origin] injection TRESIBA insulin degludec [rDNA origin] injection 6 M • • Semaglutide in patients with type 2 diabetes: real-world analysis in the Canadian LMC Diabetes Registry: the SPARE study (poster presentation 995-P) Real-world effectiveness of semaglutide in early users from a US commercially insured and Medicare Advantage population (poster presentation 1006-P) The outcomes associated with use of iDeg Lira in a large real-world cohort of patients with type 2 diabetes in Sweden (poster presentation 1110-P) The first real-world study describing change in glycated hemoglobin (HbA1c) among US patients initiating iDegLira (publication only) A multicenter, prospective, observational study that evaluates the safety and effectiveness of switching from other basal insulins to degludec, as part of routine clinical care, in patients with type 1 or type 2 diabetes: the ReFLECT study (poster presentation 374-P) A prospective, non-interventional pilot study running including twelve diabetes clinics from different parts of Sweden. Patients with type 1 diabetes using CGM were included if their treating physicians decided to offer them a NovoPen® 6 (Late-breaking poster presentation 126-LB) CGM: continuous glucose monitor novo nordisk

View entire presentation